Newron Secures Financial Backing for Critical Late-Stage Drug Trials

Newron strengthens balance sheet with €38M raise & EIB loan extension to fund Phase III trials for Evenamide, its novel schizophrenia therapy, while presenting new data.

This week marks a significant period for biopharmaceutical firm Newron SpA, as it balances scientific disclosure with financial reporting. The company is presenting new clinical data at a major schizophrenia conference while simultaneously releasing its annual report, revealing a strengthened financial position designed to support its costly final-stage development programs.

Financial Foundation for Clinical Ambitions

Newron’s 2025 financial results, published this week, show a net loss of €13.2 million, a notable shift from the prior year's profit. This change was partly driven by reduced licensing revenue. However, the company's liquidity position has improved substantially, providing a solid base for its research and development efforts.

Two key transactions in the first quarter of 2026 have significantly reinforced the balance sheet. A capital increase in February raised up to €38 million from European and Asian investors. Furthermore, in March, Newron reached an agreement with the European Investment Bank (EIB) to extend the maturity of existing loan tranches until the end of June 2028. This financial security is complemented by a newly granted patent from the European Patent Office, which protects market exclusivity for its key asset until 2044.

Scientific Spotlight on Novel Schizophrenia Therapy

Concurrently, the company is showcasing its lead candidate, Evenamide, at the SIRS congress in Florence, Italy, which began Wednesday. Evenamide is a novel glutamate modulator being developed for treatment-resistant schizophrenia. Unlike conventional antipsychotics, it selectively blocks voltage-gated sodium channels and exhibits no other known biological activity within the central nervous system.

At the conference, Newron is sharing recent findings in a workshop and three poster presentations. The data encompasses a range from preclinical animal models to updates from the ongoing Phase III clinical program.

Global Clinical Programs Advance

The newly secured capital is being channeled directly into clinical development. Two large international Phase III studies are currently underway, involving a minimum of 1,000 patients collectively, to evaluate the efficacy and safety of Evenamide as an adjunctive therapy. Progress is also being made in Asia, where partner EA Pharma initiated its own Phase III study in Japan in January 2026.

Despite this operational progress, the company's shares have faced recent pressure, declining approximately 24% on a monthly basis. The stock closed Tuesday's session at €15.66.

Governance Changes on the Horizon

The next significant corporate developments will occur at the Annual General Meeting scheduled for April 23, 2026, in Bresso, Italy. Shareholders will vote on the reconstitution of the Board of Directors. Two long-standing directors are set to step down in accordance with term limits, with George Garibaldi and Paolo Zocchi proposed as new independent members.